Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology

With more than 30 therapeutic antibodies approved worldwide, therapeutic antibodies have become a major category in the pharmaceutical market. In an effort to further expand the potential of therapeutic antibodies, several approaches are being employed, such as improving the effector functions of the antibodies, designing antibody-drug conjugates, and downsizing the antibody molecule. Among these approaches, enhancing antibody-dependent cellular cytotoxicity (ADCC), which is the major effector function of an antibody, is thought to be one of the most promising and practical approaches to make an antibody more efficacious. In this Perspective, we have provided an overview of such ADCC-enhancing technologies, while focusing mainly on our Potelligent® Technology, which has been most extensively tested in clinical trials.